Phase 1a/1b dose-escalating trial of VE303 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs VE 303 (Primary)
- Indications Clostridium-difficile-infections
- Focus Adverse reactions; First in man
- 07 Dec 2017 According to a Vedanta Biosciences media release, this study is expected to be completed in the first half of 2018.
- 07 Dec 2017 Status changed from planning to recruiting, according to a Vedanta Biosciences media release.
- 07 Nov 2017 New trial record